High-Priced Sickle Cell Gene Therapies Threaten to Exacerbate US Health Disparities and Establish New Pricing Precedents for Molecular Medicine.
J Law Med Ethics
; 50(2): 380-384, 2022.
Article
in En
| MEDLINE
| ID: mdl-35894560
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Molecular Medicine
/
Anemia, Sickle Cell
Type of study:
Health_economic_evaluation
Limits:
Humans
Country/Region as subject:
America do norte
Language:
En
Journal:
J Law Med Ethics
Journal subject:
ENFERMAGEM
/
ETICA
/
JURISPRUDENCIA
/
MEDICINA
/
PESQUISA EM SERVICOS DE SAUDE
Year:
2022
Document type:
Article
Affiliation country:
United States
Country of publication:
United kingdom